US 11,931,383 B2
Bioactive renal cells for the treatment of chronic kidney disease
Deepak Jain, Winston-Salem, NC (US); and Timothy A. Bertram, George Town (KY)
Assigned to ProKidney, Grand Cayman (KY)
Filed by ProKidney, Grand Cayman (KY)
Filed on Aug. 17, 2021, as Appl. No. 17/404,038.
Application 17/404,038 is a division of application No. 15/663,430, filed on Jul. 28, 2017, granted, now 11,123,372.
Claims priority of provisional application 62/532,338, filed on Jul. 13, 2017.
Claims priority of provisional application 62/368,919, filed on Jul. 29, 2016.
Prior Publication US 2022/0031755 A1, Feb. 3, 2022
Int. Cl. A61K 35/22 (2015.01); A61B 17/34 (2006.01); A61K 9/00 (2006.01); A61K 47/42 (2017.01)
CPC A61K 35/22 (2013.01) [A61B 17/3421 (2013.01); A61K 9/0019 (2013.01); A61K 47/42 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method for reducing rate of increase in serum creatinine (sCr) in the treatment of chronic kidney disease (CKD) in a human patient comprising an estimated glomerular filtration rate of 15 to 60 mL/min, the method comprising:
injecting into the renal cortex of at least one kidney of the patient having said CKD a composition comprising 1.0-9.0×106 cells of a selected renal cell (SRC) population per gram estimated kidney weight (/gKWest)
wherein the SRC population is enriched for renal tubular cells and exhibits a buoyant density greater than approximately 1.0419 g/mL; and
thereby reducing the rate of increase in sCr of the human patient.